US20150230736A1 - Pathlength enhancement of optical measurement of physiological blood parameters - Google Patents
Pathlength enhancement of optical measurement of physiological blood parameters Download PDFInfo
- Publication number
- US20150230736A1 US20150230736A1 US14/704,517 US201514704517A US2015230736A1 US 20150230736 A1 US20150230736 A1 US 20150230736A1 US 201514704517 A US201514704517 A US 201514704517A US 2015230736 A1 US2015230736 A1 US 2015230736A1
- Authority
- US
- United States
- Prior art keywords
- tissue
- propagation
- interface assembly
- tissue interface
- optical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000003287 optical effect Effects 0.000 title claims abstract description 286
- 239000008280 blood Substances 0.000 title claims abstract description 42
- 210000004369 blood Anatomy 0.000 title claims abstract description 42
- 238000005259 measurement Methods 0.000 title claims description 93
- 238000000034 method Methods 0.000 claims abstract description 55
- 238000012545 processing Methods 0.000 claims abstract description 40
- 230000008569 process Effects 0.000 claims description 22
- 230000010412 perfusion Effects 0.000 claims description 2
- 239000013307 optical fiber Substances 0.000 description 17
- 238000001514 detection method Methods 0.000 description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 14
- 229910052760 oxygen Inorganic materials 0.000 description 14
- 239000001301 oxygen Substances 0.000 description 14
- 238000010586 diagram Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 238000012546 transfer Methods 0.000 description 10
- 239000000306 component Substances 0.000 description 9
- 102000001554 Hemoglobins Human genes 0.000 description 7
- 108010054147 Hemoglobins Proteins 0.000 description 7
- 239000000853 adhesive Substances 0.000 description 7
- 230000001070 adhesive effect Effects 0.000 description 7
- 230000000712 assembly Effects 0.000 description 6
- 238000000429 assembly Methods 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000001934 delay Effects 0.000 description 4
- 210000001061 forehead Anatomy 0.000 description 4
- 230000010363 phase shift Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000008338 local blood flow Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000009365 direct transmission Effects 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- -1 fasteners Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000005693 optoelectronics Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000002106 pulse oximetry Methods 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 210000005010 torso Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/026—Measuring blood flow
- A61B5/0261—Measuring blood flow using optical means, e.g. infrared light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6802—Sensor mounted on worn items
- A61B5/6803—Head-worn items, e.g. helmets, masks, headphones or goggles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6844—Monitoring or controlling distance between sensor and tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7203—Signal processing specially adapted for physiological signals or for diagnostic purposes for noise prevention, reduction or removal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7221—Determining signal validity, reliability or quality
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7246—Details of waveform analysis using correlation, e.g. template matching or determination of similarity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7278—Artificial waveform generation or derivation, e.g. synthesising signals from measured signals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/02—Details of sensors specially adapted for in-vivo measurements
- A61B2562/0233—Special features of optical sensors or probes classified in A61B5/00
- A61B2562/0238—Optical sensor arrangements for performing transmission measurements on body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/02—Details of sensors specially adapted for in-vivo measurements
- A61B2562/0233—Special features of optical sensors or probes classified in A61B5/00
- A61B2562/0242—Special features of optical sensors or probes classified in A61B5/00 for varying or adjusting the optical path length in the tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2576/00—Medical imaging apparatus involving image processing or analysis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Surgery (AREA)
- Public Health (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Physiology (AREA)
- Signal Processing (AREA)
- Artificial Intelligence (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Psychiatry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Optics & Photonics (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
Systems and methods for measuring a physiological parameter of tissue in a patient are provided herein. In a first example, a method of measuring a physiological parameter of blood in a patient is provided. The method includes emitting at least two optical signals for propagation through tissue of the patient, detecting the optical signals after propagation, identifying propagation pathlengths of the optical signals, and identifying detected intensities of the optical signals. The method also includes processing at least the propagation pathlengths to scale the detected intensities for determination of a value of the physiological parameter.
Description
- This application is a continuation of and claims the benefit of U.S. application Ser. No. 13/494,630, filed on Jun. 12, 2012, and entitled “Pathlength Enhancement of Optical Measurement of Physiological Blood Parameters” which is hereby incorporated by reference in its entirety.
- Aspects of the disclosure are related to the field of medical devices, and in particular, optical measurement of physiological parameters of blood and tissue.
- Various optical-based blood measurement devices, such as fingertip pulse oximetry devices, can measure some parameters of blood flow in a patient, such as heart rate and local oxygen saturation of hemoglobin. Other techniques can be employed for determination of regional saturation of hemoglobin, such as forehead-applied devices. These devices are non-invasive measurement devices, typically employing solid-state lighting elements, such as light-emitting diodes (LEDs) or solid state lasers, to introduce light into the tissue of a patient. The light is then detected and analyzed to determine the parameters of the blood flow in the patient.
- However, conventional optical-based blood measurement devices typically are subject to patient-specific noise and inconsistencies which limits the accuracy of such devices. These patient-specific issues can include variations in tissue pigment, local blood flow or volume variations, vascular inhomogeneity of the tissue under measurement (i.e. a large vessel underneath device on tissue), tissue layer scattering, or tissue hydration, among others. Additionally, incorrect application of these devices can lead to incorrect determination of blood and tissue parameters due to optical shunting or undesired propagation of the optical signals through air gaps or blood-deficient tissue between optical emission and detection points.
- Systems and methods for measuring a physiological parameter of tissue in a patient are provided herein. In a first example, a method of measuring a physiological parameter of blood in a patient is provided. The method includes emitting at least two optical signals for propagation through tissue of the patient, detecting the optical signals after propagation, identifying propagation pathlengths of the optical signals, and identifying detected intensities of the optical signals. The method also includes processing at least the propagation pathlengths to scale the detected intensities for determination of a value of the physiological parameter.
- In another example, a method of operating a system for measuring a physiological parameter of blood in a patient is provided. The method includes emitting at least one optical signal for propagation into tissue of the patient via a tissue interface assembly, receiving the at least one optical signal after propagation, and identifying a propagation pathlength of the at least one optical signal. The method also includes processing at least the propagation pathlength to determine a state of the tissue interface assembly on the tissue.
- In another example, a system for measuring a physiological parameter of blood in a patient is provided. The system includes a tissue interface assembly configured to emit at least one optical signal for propagation into tissue of the patient and receive the at least one optical signal after propagation. The system also includes a measurement system configured to identify a propagation pathlength of the at least one optical signal, and process at least the propagation pathlength to determine a state of the tissue interface assembly on the tissue.
- Many aspects of the disclosure can be better understood with reference to the following drawings. The components in the drawings are not necessarily to scale, emphasis instead being placed upon clearly illustrating the principles of the present disclosure. Moreover, in the drawings, like reference numerals designate corresponding parts throughout the several views. While several embodiments are described in connection with these drawings, the disclosure is not limited to the embodiments disclosed herein. On the contrary, the intent is to cover all alternatives, modifications, and equivalents.
-
FIG. 1 is a system diagram illustrating a system for measuring a physiological parameter of blood in a patient. -
FIG. 2 is a flow diagram illustrating a method of operation of a system for measuring a physiological parameter of blood in a patient. -
FIG. 3 is a system diagram illustrating a system for measuring a physiological parameter of blood in a patient. -
FIG. 4 is a flow diagram illustrating a method of operation of a system for measuring a physiological parameter of blood in a patient. -
FIG. 5 is a system diagram illustrating a system for measuring a physiological parameter of blood in a patient. -
FIG. 6 is a system diagram illustrating a measurement environment for measuring a physiological parameter of blood in a patient. -
FIG. 7 is a flow diagram illustrating a method of operating a system for measuring a physiological parameter of blood in a patient. - Various physiological parameters of tissue and blood of a patient can be determined non-invasively, such as optically. In one example, optical signals introduced into the tissue of the patient are modulated according to a high-frequency modulation signal to create a photon density wave (PDW) optical signal in the tissue undergoing measurement. In PDW techniques, an optical signal with a carrier wavelength is intensity modulated at a high frequency, on the order of 400-500 megahertz (MHz), although other frequencies are possible. Due to the interaction between the tissue or blood and the PDW optical signal, various characteristics of the PDW optical signal can be affected, such as through scattering or propagation by various components of the tissue and blood. The various physiological parameters can include any parameter associated with the blood or tissue of the patient, such as hemoglobin concentration (tHb), regional oxygen saturation (rSO2), arterial oxygen saturation (SpO2), heart rate, lipid concentrations, among other parameters, including combinations thereof.
- As a first example of a system for applying optical signals to tissue of a patient,
FIG. 1 is presented.FIG. 1 is a systemdiagram illustrating system 100 for measuring a physiological parameter of blood in a patient.FIG. 1 showssystem 100 as includingtissue interface assembly 110,measurement system 120,tissue 130, andsignal link 140 which includes links 141-142. A representative view of the elements ofsystem 100 is included inFIG. 1 to highlight these particular elements. It should be understood the features ofFIG. 1 are merely intended to highlight various elements ofsystem 100, and are not intended to be exact wireframe representations of the elements ofsystem 100; variations are possible. - Signals generated by
measurement system 120 are applied totissue 130 for measurement of a physiological parameter, as indicated by optical signals 150-151. In this example, optical signals are transferred viaoptical link 141 totissue interface assembly 110 for propagation intissue 130. In other examples,link 141 is an electrical link and is configured to drive an optical emitter included withintissue interface assembly 110. Optical signals 150-151 are detected throughtissue 130 and transferred tomeasurement system 120 overlink 142. In this example, optical signals are transferred viaoptical link 142 tomeasurement system 120 for detection and processing. In other examples, a detector element is included intissue interface assembly 110, and electrical signaling representative of the detected optical signals 150-151 are transferred overlink 142.Optical link 141 is terminated at a first location oftissue interface assembly 110 and configured to emit optical signals 150-151 for propagation intissue 130 at that first location Likewise,optical link 142 is terminated as a second location oftissue interface assembly 110 and configured to receive optical signals 150-151 after propagation. Distance ‘d1’ ofFIG. 1 indicates the distance between the first location and the second location. Example distances for d1 are 5 mm or 10 mm, although variations are possible. - In
FIG. 1 , optical signals 150-151 are introduced at a first location and received at a second location. Optical signals 150-151 are each shown to propagate a different pathlength intissue 130. The difference in pathlength can be caused by different properties oftissue 130 encountered by each optical signal or by different properties of optical signals 150-151. For example, when each of optical signals 150-151 comprises a different carrier wavelength, different propagation pathlengths throughtissue 130 can occur. Different frequencies or wavelengths of optical signals can have different inherent absorption and propagation characteristics in blood and/or tissue. For example, red optical wavelengths typically do not traverse as much blood/tissue as infrared (IR) wavelengths since melanin in the tissue absorbs red better than IR. Thus, the propagation pathway for an IR wavelength signal may be longer than a red wavelength signal for the same distance d1. As a specific example, a red carrier wavelength is 660 nanometers and an IR carrier wavelength is 900 nanometers, although other carrier wavelengths are possible. In operation,measurement system 120 can process the different propagation pathlengths to scale detected intensities for each of optical signals 150-151 for determination of a value of a physiological parameter oftissue 130. It should be understood that the propagation pathlengths shown inFIG. 1 are merely representative of different propagations of the associated optical signals, and the pathlengths can comprise mean pathlengths. -
FIG. 2 is a flow diagram illustrating a method of operation of a system for measuring a physiological parameter of blood in a patient. Although the operations ofFIG. 2 are discussed below as applied tosystem 100 found inFIG. 1 , it should be understood that the operations ofFIG. 2 can also be applied tosystem 300 ofFIG. 3 ,system 500 ofFIG. 5 , orsystem 600 ofFIG. 6 , as well as other systems. The operations ofFIG. 2 are referenced herein parenthetically. - In
FIG. 2 ,tissue interface assembly 110 emits (201) optical signals for propagation through tissue of the patient. In the example shown inFIG. 1 ,measurement system 120 generates and transfers at least optical signals 150-151 overlink 141 for propagation throughtissue 130. These optical signals can include a single or multiple signals with a single or multiple carrier wavelengths. For example, both an infrared and visible based optical signal can be transferred overlink 141.Tissue interface assembly 110 receives optical signals 150-151 and emits them for propagation throughtissue 130. Optical interface elements, such as prisms, lenses, waveguides, and the like, can be included intissue interface assembly 110 to couple optical signals 150-151 fromlink 141 totissue 130. It should be noted that in alternate examples, electrical signals are transferred bymeasurement system 120 overlink 141 and optical emitter elements intissue interface assembly 110, such as solid state laser elements and the like, receive the electrical signals and emit optical signals 150-151 intotissue 130 responsive to the electrical signals. -
Tissue interface assembly 110 detects (202) the optical signals after propagation. As shown inFIG. 1 , optical signals 150-151 propagate throughtissue 130, and are received bytissue interface assembly 110. These optical signals are both transferred overlink 142 for receipt and processing bymeasurement system 120. Optical interface elements, such as prisms, lenses, waveguides, and the like, can be included intissue interface assembly 110 to couple optical signals fromtissue 130 to link 142. It should be noted that in alternate examples, optical detection elements intissue interface assembly 110, such as photodetector elements and the like, receive optical signals 150-151 and transfer electrical signals overlink 142 responsive to the optical signals. -
Measurement system 120 identifies (203) propagation pathlengths of the optical signals. As shown inFIG. 1 , optical signals 150-151 may each have different propagation properties throughtissue 130, such as propagation pathlengths intissue 130. After receiving the optical signals, or representations thereof, overlink 142,measurement system 120 processes at least the optical signals to determine propagation pathlengths. In some examples,measurement system 120 processes phase delays or phase shifts of the optical signals to determine the propagation pathlengths. Other information can be processed to identify the propagation pathlengths, such as reference signals representing baseline phase delays for each optical signal, a carrier wavelength of each of the optical signals, propagation speeds or properties oftissue 130, or a separation distance between emission and detection points (such as ‘d1’), among other information, including combinations and variations thereof. It should be understood that the propagation pathlengths shown inFIG. 1 are merely representative and can vary.FIG. 1 also showstissue interface assembly 110 coupled totissue 130 without gaps, and thus optical signals 150-151 are introduced intotissue 130. In other examples, such as those discussed inFIGS. 5-7 ,tissue interface assembly 110 may not properly mate or couple withtissue 130 and thus optical signals 150-151 may have different propagation pathlengths. -
Measurement system 120 identifies (204) detected intensities of the optical signals. The intensities can be different for each of optical signals 150-151 due to the propagation throughtissue 130, the properties oftissue 130 and components withintissue 130, such as blood, among others. After receiving the optical signals, or representations thereof, overlink 142,measurement system 120 processes at least the optical signals to determine intensities after propagation throughtissue 130. The intensities can be identified as brightness, luminosity, or signal strength and the like. In examples where detector elements are included intissue interface assembly 110, the detector elements can convert the optical signals into electrical representations, andmeasurement system 120 can process the electrical representations to determine the intensities. -
Measurement system 120 processes (205) at least the propagation pathlengths to scale the detected intensities for determination of a value of a physiological parameter. Each optical signal 150-151 can have different propagation properties such as a propagation pathlength. These differences in propagation pathlength can lead to inaccuracies and errors in the calculation and processing of the optical signal intensities or other properties to identify values of physiological parameters. Therefore, measured properties of the optical signals, such as intensity, are scaled according to the associated propagation pathlengths of the optical signals and the scaled values are used in determination of the value of the physiological parameter. As noted herein, the physiological parameter can include any parameter associated with the blood or tissue of the patient, such as hemoglobin concentration (tHb), regional oxygen saturation (rSO2), arterial oxygen saturation (SpO2), heart rate, lipid concentrations, among other parameters, including combinations thereof. - In a specific example, such as when optical signals with multiple carrier wavelengths are employed, a ratiometric relationship is employed between detected intensities of at least two optical signals to determine a value of a physiological parameter. Propagation pathlength variations encountered during propagation of the optical signals can disturb these ratiometric relationships. Pathlength variations can be caused by different propagation pathlengths in tissue for different carrier wavelengths, invalid or improper sensor application on tissue, or insufficiently perfused tissue under measurement, among other causes. Thus, the propagation pathlengths of the optical signals can be used to scale the ratiometric relationships to compensate for different propagation pathlengths and reduce errors and inconsistencies in determinations of values of physiological parameters.
-
FIG. 3 is presented as a second example of a system for applying optical signals to tissue of a patient.FIG. 3 is a systemdiagram illustrating system 300 for measuring a physiological parameter of blood in a patient.System 300 can be an alternate configuration forsystem 100, although other configurations can be employed.FIG. 3 showssystem 300 as includingtissue interface assembly 310,measurement system 320,tissue 330, and signal link 340 which includes links 341-343. A representative view of the elements ofsystem 300 is included inFIG. 3 to highlight these particular elements. It should be understood the features ofFIG. 3 are merely intended to highlight various elements ofsystem 300, and are not intended to be exact wireframe representations of the elements ofsystem 300; variations are possible. - Signals generated by
measurement system 320 are applied totissue 330 for measurement of a physiological parameter, as indicated by optical signals 350-351. In this example, optical signals are transferred viaoptical link 341 totissue interface assembly 310 for propagation intissue 330. In other examples, link 341 is an electrical link and is configured to drive an optical emitter (or emitters) included withintissue interface assembly 310. Optical signals 350-351 are detected throughtissue 330 and transferred tomeasurement system 320 over both link 342 and link 343. In this example, optical signals are transferred via optical links 342-343 tomeasurement system 320 for detection and processing. In other examples, a detector element (or elements) is included intissue interface assembly 310, and electrical signaling representative of the detected optical signals 350-351 are transferred over links 342-343. -
Optical link 341 is terminated at a first location intissue interface assembly 310 and configured to emit optical signals 350-351 for propagation intissue 330 at that first location.Optical link 342 is terminated as a second location intissue interface assembly 310 and configured to receive optical signals 350-351 after propagation.Optical link 343 is terminated at a third location intissue interface assembly 310 and configured to receive optical signals 350-351 after propagation. Distance ‘d2’ ofFIG. 3 indicates the distance between the first location and the second location, and distance ‘d3’ ofFIG. 3 indicates the distance between the first location and the third location. Example distances include 5 mm for d2 and 10 mm for d3, although variations are possible. Thus, optical signals 350-351 are each introduced at a first location and both are received at a second location associated withlink 342 and a third location associated withlink 343. - Optical signals 350-351 in
FIG. 3 include optical signals of at least two carrier wavelengths, and a portion of each optical signal is received at each detection point shown. Optical signals 350-351 can also each propagate a different pathlength intissue 330. The difference in pathlength can be caused by different properties oftissue 330 encountered by each optical signal, the different detection distances d2 and d3, or by different properties of optical signals 350-351, such as those discussed above forFIG. 1 , including combinations thereof. Additionally, a portion of each of optical signals 350-351 is transferred over each optical link 342-343. In operation,measurement system 320 can process the different propagation pathlengths to scale detected intensities for each of optical signals 350-351 for determination of a value of a physiological parameter oftissue 330. It should be understood that the propagation pathlengths shown inFIG. 3 are merely representative of different propagations of the associated optical signals, and the pathlengths can comprise mean pathlengths. -
FIG. 4 is a flow diagram illustrating a method of operation of a system for measuring a physiological parameter of blood in a patient. Although the operations ofFIG. 4 are discussed below as applied tosystem 300 found inFIG. 3 , it should be understood that the operations ofFIG. 4 can also be applied tosystem 100 ofFIG. 1 ,system 500 ofFIG. 5 , orsystem 600 ofFIG. 6 , as well as other systems. The operations ofFIG. 4 are referenced herein parenthetically. - In
FIG. 4 ,tissue interface assembly 310 emits (401) optical signals for propagation through tissue of the patient. In the example shown inFIG. 3 ,measurement system 320 generates and transfers at least optical signals 350-351 overlink 341 for propagation throughtissue 330. In this example, optical signals 350-351 can comprise infrared and visible optical components which are both transferred overlink 341.Tissue interface assembly 310 receives optical signals 350-351 and emits them for propagation throughtissue 330. Optical interface elements, such as prisms, lenses, waveguides, and the like, can be included intissue interface assembly 310 to couple optical signals 350-351 fromlink 341 totissue 330. It should be noted that in alternate examples, electrical signals are transferred bymeasurement system 320 overlink 341 and optical emitter elements intissue interface assembly 310, such as solid state laser elements and the like, receive the electrical signals and emit optical signals 350-351 intotissue 330 responsive to the electrical signals. -
Tissue interface assembly 310 detects (402) the optical signals after propagation. As shown inFIG. 3 , optical signals 350-351 propagate throughtissue 330, and are received bytissue interface assembly 310. A first portion of optical signals 350-351 is received bytissue interface assembly 310 for transfer overlink 342 and a second portion of optical signals 350-351 is received bytissue interface assembly 310 for transfer overlink 343. These optical signals are transferred over the respective links 342-343 for receipt and processing bymeasurement system 320. Optical interface elements, such as prisms, lenses, waveguides, and the like, can be included intissue interface assembly 310 to couple optical signals fromtissue 330 to links 342-343. It should be noted that in alternate examples, optical detection elements intissue interface assembly 310, such as photodetector elements and the like, receive optical signals 350-351 and transfer electrical signals over links 342-343 responsive to the optical signals. -
Measurement system 320 identifies (403) propagation pathlengths of the optical signals. As shown inFIG. 3 , optical signals 350-351 each have different propagation properties throughtissue 330, such as propagation pathlengths intissue 330. Also, portions of optical signals 350-351 are detected at different detection distances from the input point, namely d2 and d3. After receiving the optical signals, or representations thereof, over links 342-343,measurement system 320 processes at least the optical signals and separation distances d2 and d3 to determine propagation pathlengths. In some examples,measurement system 320 processes phase delays or phase shifts of the optical signals to determine the propagation pathlengths. -
FIG. 3 shows a first portion of optical signals 350-351 received at distance d2, and a second portion of optical signals 350-351 received at distance d3. A first set of propagation pathlengths for signal components of the different carrier wavelengths of optical signals 350-351 can be determined for the first portion received at the first distance d2, and a second set of propagation pathlengths for signal components of the different carrier wavelengths of optical signals 350-351 can be determined for the second portion received at the second distance d3. In examples with two carrier wavelengths, such as visible and infrared, four total propagation pathlengths can be determined. Specifically, a propagation pathlength can be determined for each of the visible and infrared signal portions received at distance d2, and a propagation pathlength can be determined for each of the visible and infrared signal portions received at distance d3. It should be understood that other carrier wavelengths or frequencies can be employed. - Other information can be processed to identify the propagation pathlengths, such as reference signals representing baseline phase delays for each optical signal, a carrier wavelength of each of the optical signals, or propagation speeds through
tissue 330, or properties oftissue 330, among other information, including combinations and variations thereof. It should be understood that the propagation pathlengths shown inFIG. 3 are merely representative in and can vary.FIG. 3 also showstissue interface assembly 310 coupled totissue 330 without gaps, and thus optical signals 350-351 are introduced intotissue 330. In other examples, such as those discussed inFIGS. 5-7 ,tissue interface assembly 310 may not properly mate or couple withtissue 330 and thus optical signals 350-351 may have different propagation pathlengths. -
Measurement system 320 identifies (404) detected intensities of the optical signals. The intensities can be different for each of optical signals 350-351 due to the propagation throughtissue 330, distances d2 and d3, the properties oftissue 330, and components withintissue 330, such as blood, among others. After receiving the optical signals, or representations thereof, over links 342-343,measurement system 320 processes at least the optical signals to determine intensities after propagation throughtissue 330. The intensities can be identified as brightness, luminosity, or signal strength and the like. In examples where detector elements are included intissue interface assembly 310, the detector elements can convert the optical signals into electrical representations, andmeasurement system 320 can process the electrical representations to determine the intensities. -
Measurement system 320 processes (405) at least the propagation pathlengths and the separation distances to scale the detected intensities for determination of a value of a physiological parameter. As discussed above, each of optical signals 350-351 can have different propagation properties such as a propagation pathlength. These differences in propagation pathlength can lead to inaccuracies and errors in the calculation and processing of the optical signal intensities or other properties to identify values of physiological parameters. - Different carrier wavelengths of optical signals 350-351 can propagate differently through
tissue 330 due to the influence of absorbent or reflectance differences of components oftissue 330 for different wavelengths, different propagation speeds intissue 330 for different wavelengths, or other wavelength-dependent propagation properties, and thus may penetrate to different depths intissue 330 or traverse different propagation paths intissue 330. Therefore, measured properties of the optical signals, such as intensity, are scaled according to the associated propagation pathlengths of the optical signals and the scaled values are used in determination of the value of the physiological parameter. Also, since optical signals 350-351 are received at two distances, namely distances d2 and d3, the propagation pathways determined for each distance can be employed to scale the intensities for the optical signals received at each detection distance. In some examples, processing at least the propagation pathlengths to scale the detected intensities comprises processing a first carrier wavelength of a first optical signal and a second carrier wavelength of a second optical signal, distances between a first emission location and each of a second receive location and a third receive location, and the propagation pathlengths of the first optical signal and the second optical signal to scale the detected intensities of the first optical signal and the second optical signal. - In some examples, a ratio of intensities of two carrier wavelength portions of the optical signals are scaled by a ratio of associated propagation pathlengths for the optical signals associated with the two carrier wavelength portions. As noted herein, the physiological parameter can include any parameter associated with the blood or tissue of the patient, such as hemoglobin concentration (tHb), regional oxygen saturation (rSO2), arterial oxygen saturation (SpO2), heart rate, lipid concentrations, among other parameters, including combinations thereof.
- Referring back to
FIGS. 1 and 3 ,tissue interface assembly 110 andtissue interface 330 each can comprise a physical structure having a surface that couples to biological tissue, namelytissue Tissue interface assembly 110 includes a mechanical configuration to position and hold optical links 141-142 in a desired arrangement relative totissue 130.Tissue interface assembly 310 can include similar configurations for optical links 341-343. These configurations can include elements such as grooves, channels, holes, snap-fit features, or other elements to route optical fibers or optical links to a desired position in the tissue interface assembly.Tissue interface assemblies tissue interface assemblies tissue interface assemblies tissue interface assemblies tissue interface assemblies -
Tissue -
Measurement systems Measurement systems Measurement systems Measurement systems - Optical links 141-142 and 341-343 each comprise an optical waveguide, such as an optical fiber, and each use glass, polymer, air, space, or some other material as the transport media for transmission of light, and can each include multimode fiber (MMF) or single mode fiber (SMF) materials. A sheath or loom can be employed to bundle associated optical links 141-142 and 341-343 together or with further optical links for convenience, as indicated by
links measurement system FIGS. 1 and 3 , comprising channels, forward links, reverse links, frequencies, wavelengths, modulation frequencies, carriers, timeslots, spreading codes, logical transportation links, or communication directions. - Also, although
FIGS. 1 and 3 each illustrate optical links 141-142 and 341-343, it should be understood that any number of input links and output links can be included, as well as any associated optical source and detector equipment. For example, a tissue interface assembly may route many optical fibers to different physical locations on the tissue, and these optical fibers can carry optical signals of different wavelengths. Alternatively, or in addition, a tissue interface assembly may have measurement links positioned at different distances from input links or positioned over different anatomical structures. Also, althoughFIGS. 1 and 3 are each shown as carrying optical signals, in further examples a direct optical source can be included in the tissue interface assembly and applied to the tissue. Such direct light sources can include light-emitting diodes (LEDs), laser sources, solid state laser diodes, or other signal sources, including combinations thereof. - The term ‘optical’ or ‘light’ is used herein for convenience. It should be understood that the applied and detected signals are not limited to visible light, and can comprise any photonic, electromagnetic, or energy signals, such as visible, infrared, near-infrared, ultraviolet, radio, x-ray, gamma, or other signals. Additionally, the use of optical fibers or optical cables herein is merely representative of a waveguide used for propagating signals between a transceiver and tissue of a patient. Suitable waveguides would be employed for different electromagnetic signal types.
-
FIGS. 5 and 6 include further examples of systems for measuring a physiological parameter of blood in a patient, andFIG. 7 includes an example method of operation ofsystem 500 ofFIG. 5 orsystem 600 ofFIG. 6 . The elements ofFIGS. 5 and 6 can include elements similar to those found inFIGS. 1 and 3 , although other configurations are possible.FIG. 5 illustrates asystem 500 for measuring regional oxygen saturation of blood in tissue, whileFIG. 6 illustrates an example ofsystem 500 employed on a forehead portion of a patent to measure regional oxygen saturation of blood in the patient. - Regional oxygen saturation measurement typically includes steady state or “DC” measurement techniques, where pulsatile perturbation of tissue by vascular activity is not significant. Also, longer distances are employed in regional oxygen saturation measurement, such as 10 millimeters (mm) and 40 mm from an optical signal input point to detection points. Also, a lower frequency of modulation of any associated optical signals is typically employed, such as 50-100 megahertz (MHz) versus 400-500 MHz for photon-density wave (PDW) techniques. Although
FIGS. 5-7 discuss regional oxygen saturation measurement, the systems and techniques can be applied to other measurements such as the PDW techniques described above inFIGS. 1-4 . -
FIG. 5 includessystem 500 which includes tissue interface elements 510-512,measurement system 520,tissue 530, andoptical link 540. A representative view of the elements ofsystem 500 is included inFIG. 5 to highlight these particular elements. It should be understood the features ofFIG. 5 are merely intended to highlight various elements ofsystem 500, and are not intended to be exact wireframe representations of the elements ofsystem 500; - variations are possible.
- Signals generated by
measurement system 520 are emitted for propagation intotissue 530 for measurement of a physiological parameter, as indicated by optical signals 550-551. In this example, optical signals are transferred viaoptical fiber 541 totissue interface element 510 for propagation intotissue 530. In other examples,optical fiber 541 is instead an electrical link and is configured to drive an optical emitter included withintissue interface element 510. Optical signals 550-551 are received after propagation and transferred tomeasurement system 520 over associated optical fiber 542-543. In this example, optical signals are transferred via optical fibers 542-542 tomeasurement system 520 for detection and processing. In other examples, detector elements are included in tissue interface elements 511-512, and electrical signaling representative of the detected optical signals 550-551 are instead transferred over associated link 542-543.Optical fiber 541 is terminated intissue interface element 510 and configured to emit optical signals 550-551 for propagation intotissue 530 fromtissue interface element 510. Likewise,optical fiber 542 is terminated intissue interface element 511 and configured to receiveoptical signal 550 after propagation, andoptical fiber 543 is terminate intissue interface element 512 and configured to receiveoptical signal 551 after propagation. - In
FIG. 5 , optical signals 550-551 are both introduced at a first location and each are received at different locations. Optical signals 550-551 are each shown to propagate a different pathlength before receipt. As shown inFIG. 5 , tissue interface elements 511-512 are not coupled totissue 530, and instead each hasgap 560 betweentissue 530 and the associated tissue interface element. Thus, the majority of optical energy associated with optical signals 550-551 travels throughgap 560, such as air or space, between tissue interface elements 510-512 and does not propagate intotissue 530 as intended. It should be understood that the propagation pathlengths shown inFIG. 5 are merely representative of different propagations of the associated optical signals, and the pathlengths can comprise mean pathlengths. -
FIG. 5 also shows a detailed representation ofmeasurement system 520.Measurement system 120 ofFIG. 1 ormeasurement system 320 ofFIG. 3 can include elements similar tomeasurement system 520, although other configurations are possible. Likewise,measurement system 520 can include equipment and systems as discussed herein formeasurement system 120 andmeasurement system 320, although variations are possible.Measurement system 520 comprisessignal interface 526,processing system 527, andmemory 528. - In operation,
processing system 527 is operatively linked to signalinterface 526 andmemory 527.Processing system 527 is capable of executing software stored inmemory 527. When executing the software,processing system 527 drivesmeasurement system 520 to operate as described herein.Measurement system 520 can also include a user interface, such as user input devices and a display for monitoring, altering, or controlling a status or configuration ofmeasurement system 520. -
Processing system 527 may be implemented within a single processing device but may also be distributed across multiple processing devices or sub-systems that cooperate in executing program instructions. Examples ofprocessing system 527 include general purpose central processing units, microprocessors, application specific processors, and logic devices, as well as any other type of processing device. -
Signal interface 526 includes optical interfaces for coupling optical signals generated bymeasurement system 520 tooptical fiber 541 as well as for coupling optical signals received by tissue interface elements over optical fibers 542-543. Examples ofsignal interface 526 include optical couplers, optical emitters and detector sensors and circuitry, optical connectors, transceivers, or other optical interfacing elements. In examples wheremeasurement system 520 instead transfers or receives electrical signals to/from a tissue interface element or assembly instead of optical signals, associated electrical interfaces can be included insignal interface 526, such as transceivers, RF couplers, filters, electrical connectors, or other electrical interfacing equipment. -
Memory 528 may comprise any storage media readable byprocessing system 527 and capable of storing software.Memory 528 may include volatile and nonvolatile, removable and non-removable media implemented in any method or technology for storage of information, such as computer readable instructions, data structures, program modules, or other data.Memory 528 may be implemented as a single storage device but may also be implemented across multiple storage devices or sub-systems.Memory 528 may comprise additional elements, such as a controller, capable of communicating withprocessing system 527. Examples of storage media include random access memory, read only memory, and flash memory, as well as any combination or variation thereof, or any other type of storage media. In some implementations, the storage media may be a non-transitory storage media. In some implementations, at least a portion of the storage media may be transitory. It should be understood that in no case is the storage media a propagated signal. - Software stored on or in
memory 528 may comprise computer program instructions, firmware, or some other form of machine-readable processing instructions having processes that when executed by processingsystem 527direct measurement system 520 to operate as described herein. For example, software drivesmeasurement system 520 to generate and transfer optical signals for propagation into tissue, receive optical signals after propagation, determine propagation pathlengths of the optical signals, determine values of physiological parameters, and identify states of a tissue interface assemblies or elements, among other operations. The software may also include user software applications. The software may be implemented as a single application or as multiple applications. In general, the software may, when loaded intoprocessing system 527 and executed, transformprocessing system 527 from a general-purpose device into a special-purpose device customized as described herein. -
FIG. 6 illustratessystem 600 as an example ofsystem 500 employed on a forehead portion of a patent. Specifically,system 600 includesheadband 610,tissue interface assembly 613, andpatient 630.Tissue interface assembly 613 includes tissue interface elements 510-512 fromsystem 500.Patient 630 is included as an example oftissue 530, and is merely representative of a patient undergoing measurement, variations are possible.Headband 610 comprises a band which is configured to fit around the head of a patient, and may be composed of fabric, fasteners, adhesive materials, flexible materials, or other elements to couple elements 510-512 to the forehead ofpatient 630. In some examples,headband 610 is omitted and elements 510-512 are coupled topatient 630 by adhesive materials. Alternately,headband 610 could instead be a finger clamp, wrist band, leg band, or other patient interface element. Associated cabling, links, and measurement systems are omitted fromFIG. 6 for clarity. - As shown in
FIG. 6 , tissue interface elements 510-512 are spaced apart. Example distances can include 10 millimeters for a distance betweenelement 510 andelement 511, and 40 millimeters for a distance betweenelement 510 andelement 512. Other spacing or separation distances are possible. -
FIG. 7 is a flow diagram illustrating a method of operating a system for measuring a physiological parameter of blood in a patient. Although the operations ofFIG. 7 are discussed below as applied tosystem 500 inFIG. 5 orsystem 600 inFIG. 6 , it should be understood that the operations ofFIG. 7 can also be applied tosystem 100 ofFIG. 1 ,system 300 ofFIG. 3 , as well as other systems. Also, although the operations ofFIG. 7 discuss tissue interface elements 510-512 ofFIG. 5 , it should be understood thattissue interface assembly 613 andheadband 610 ofFIG. 6 can instead be employed. The operations ofFIG. 7 are referenced herein parenthetically. - In
FIG. 7 ,tissue interface element 510 emits (701) optical signals for propagation through tissue of the patient. In the example shown inFIG. 5 ,measurement system 520 generates and transfers at least optical signals 550-551 overlink 541 for propagation throughtissue 530. These optical signals can include a single or multiple signals with a single or multiple carrier frequencies. For example, both an infrared and visible optical signal can be transferred overlink 541.Tissue interface element 510 receives optical signals 550-551 overlink 541 and emits the optical signals for propagation throughtissue 530. Optical interface elements, such as prisms, lenses, waveguides, and the like, can be included intissue interface element 510 to couple optical signals 550-551 fromlink 541 totissue 530. It should be noted that in alternate examples, electrical signals are transferred bymeasurement system 520 overlink 541 and optical emitter elements intissue interface element 510, such as solid state laser elements and the like, receive the electrical signals and emit optical signals 550-551 for propagation intotissue 530 responsive to the electrical signals. - Tissue interface elements 511-512 each receive (702) the optical signals after propagation. As shown in
FIG. 5 , optical signals 550-551 do not significantly propagate intotissue 530 and are received by tissue interface elements 511-512 via propagation across the surface oftissue 530 and throughgap 560 by reflection and direct transmission. These received optical signals are transferred over associated links 542-543 for receipt and processing bymeasurement system 520. Optical interface elements, such as prisms, lenses, waveguides, and the like, can be included in tissue interface elements 511-512 to couple received optical signals to associated links 542-543. It should be noted that in alternate examples, optical detection elements in tissue interface elements 511-512, such as photodetector elements and the like, receive optical signals 550-551 and transfer electrical signals over associated links 542-543 responsive to the optical signals. -
Measurement system 520 identifies (703) a propagation pathlength of at least one optical signal. As shown inFIG. 5 , optical signals 550-551 may each have different propagation properties throughgap 560, such as propagation pathlengths throughgap 560. After receiving an optical signal, or representation thereof, over any of links 542-543,measurement system 520 processes at least one optical signal to determine a propagation pathlength. - In some examples,
measurement system 520 processes a phase delay or phase shift of an optical signal to determine the propagation pathlength. The phase delay or phase shift can be in relation to a reference signal, or to a version of the associated optical signal that does not propagate fromtissue interface element 510, such as an optical signal internally shunted inmeasurement system 520. In further examples, a reference measurement signal is included inlink 540 which receives optical signals fromlink 541 within or neartissue interface element 510 without significant propagation external to the tissue interface element (system 500 can include a further reference optical link in such examples). - Other information can be processed to identify the propagation pathlengths, such as a reference signal internal to
measurement system 520 representing baseline phase for an optical signal, a carrier wavelength of the optical signal, a propagation speed of the optical signal in tissue, properties oftissue 530, or a separation distance between emission and detection points, among other information, including combinations and variations thereof. It should be understood that the propagation pathlengths shown inFIG. 5 are merely representative and can vary.FIG. 5 also showsgap 560 between tissue interface elements 510-511 andtissue 530, different gap sizes and configurations are possible. In further examples, tissue interface elements 510-511, or ones thereof, are coupled totissue 530 without gaps, and thus optical signals 550-551 are introduced intotissue 530. -
Measurement system 520 processes (704) at least one propagation pathlength to determine a state of tissue interface elements 510-512 ontissue 530. In some examples, processing at least one propagation pathlength of an optical signal to determine the state of the tissue interface elements on the tissue includes comparing the propagation pathlength of the optical signal to a pathlength range to determine an invalid application of the tissue interface element. Improper or invalid tissue interface element applications to tissue include shunting of optical signals between emission and detection elements without significant penetration or propagation intotissue 530. Other tissue applications can include variations in tissue pigmentation, variations in local blood flow or volume, vascular inhomogeneities (such as large vessel underneath tissue interface elements), tissue layer scattering, or tissue hydration variations, including combinations and variations thereof. The pathlength range can be an expected range of a propagation pathlength for an optical signal properly introduced intotissue 530 and after propagation throughtissue 530. The range can include a first threshold propagation pathlength indicating a minimum propagation pathlength and a second threshold propagation pathlength including a maximum propagation pathlength. If the detected propagation pathlength does not meet the first or second thresholds, then the optical signal is determined to have propagated an undesired or invalid path, such as throughgap 560, through insufficiently perfused tissue, or other paths other than the desired path through sufficiently perfusedtissue 530. - In another example, processing at least the propagation pathlength to determine the state of the tissue interface elements on the tissue comprises determining the state of the tissue interface assembly as including
gap 560 between thetissue interface element 510 introducing the optical signals andtissue 530. In yet another example, processing at least the propagation pathlength to determine the state of the tissue interface elements on the tissue comprises determining the state of at least one of tissue interface elements 511-512 as includinggap 560 between the associated tissue interface element detecting or receiving the optical signal andtissue 530. In yet further examples, an invalid application of the tissue interface elements 510-512 comprises an application of ones of tissue interface elements onto tissue perfused by blood below a perfusion threshold. - If the state of tissue interface elements 510-512 on
tissue 530 indicates a proper application of the tissue interface elements, thenmeasurement system 520 can process a propagation pathlength of at least one detected optical signal and a detected intensity of the at least one optical signal to determine of a value of the physiological parameter. As noted herein, the physiological parameter can include any parameter associated with the blood or tissue of the patient, such as hemoglobin concentration (tHb), regional oxygen saturation (rSO2), arterial oxygen saturation (SpO2), heart rate, lipid concentrations, among other parameters, including combinations thereof. - The included descriptions and figures depict specific embodiments to teach those skilled in the art how to make and use the best mode. For the purpose of teaching inventive principles, some conventional aspects have been simplified or omitted. Those skilled in the art will appreciate variations from these embodiments that fall within the scope of the invention. Those skilled in the art will also appreciate that the features described above can be combined in various ways to form multiple embodiments. As a result, the invention is not limited to the specific embodiments described above, but only by the claims and their equivalents.
Claims (14)
1. A method of operating a system for measuring a physiological parameter of blood in a patient, the method comprising:
emitting at least one optical signal for propagation into tissue of the patient via a tissue interface assembly;
receiving the at least one optical signal after propagation;
identifying a propagation pathlength of the at least one optical signal; and
processing at least the propagation pathlength to determine a state of the tissue interface assembly on the tissue.
2. The method of claim 1 , wherein processing at least the propagation pathlength to determine the state of the tissue interface assembly on the tissue comprises comparing the propagation pathlength of the at least one optical signal to a pathlength range to determine an invalid application of the tissue interface assembly.
3. The method of claim 2 , wherein the invalid application of the tissue interface assembly comprises a gap between the tissue and the tissue interface assembly.
4. The method of claim 2 , wherein the invalid application of the tissue interface assembly comprises an application of the tissue interface assembly onto tissue perfused by blood below a perfusion threshold.
5. The method of claim 1 , wherein identifying the propagation pathlength of the at least one optical signal comprises determining a phase delay of the at least one optical signal and processing the phase delay with a propagation speed through the tissue for the at least one optical signal.
6. The method of claim 1 , wherein emitting the at least one optical signal for propagation into tissue of the patient via the tissue interface assembly comprises emitting the at least one optical signal through at least a gap between the tissue interface assembly and the tissue; and
wherein processing at least the propagation pathlength to determine the state of the tissue interface assembly on the tissue comprises determining the state of the tissue interface assembly as including the gap between the tissue interface assembly and the tissue.
7. The method of claim 1 , wherein receiving the at least one optical signal after propagation comprises receiving the at least one optical signal after propagation through at least a gap between the tissue interface assembly and the tissue; and
wherein processing at least the propagation pathlength to determine the state of the tissue interface assembly on the tissue comprises determining the state of the tissue interface assembly as including the gap between the tissue interface assembly and the tissue.
8. The method of claim 1 , further comprising:
processing at least the propagation pathlength of the at least one optical signal and a detected intensity of the at least one optical signal to determine of a value of the physiological parameter when the state of the tissue interface assembly on the tissue indicates a proper application of the tissue interface assembly.
9. A system for measuring a physiological parameter of blood in a patient, comprising:
a tissue interface assembly configured to emit at least one optical signal for propagation into tissue of the patient and receive the at least one optical signal after propagation; and
a measurement system configured to identify a propagation pathlength of the at least one optical signal, and process at least the propagation pathlength to determine a state of the tissue interface assembly on the tissue.
10. The system of claim 9 , wherein the measurement system is configured to compare the propagation pathlength of the at least one optical signal to a pathlength range to determine an invalid application of the tissue interface assembly as the state of the tissue interface assembly on the tissue.
11. The system of claim 10 , wherein the invalid application of the tissue interface assembly comprises a gap between the tissue and the tissue interface assembly.
12. The system of claim 9 , wherein the tissue interface assembly is configured to emit the at least one optical signal through at least a gap between the tissue interface assembly and the tissue, and wherein the measurement system is configured to process at least the propagation pathlength to determine the state of the tissue interface assembly on the tissue as including the gap between the tissue interface assembly and the tissue.
13. The system of claim 9 , wherein the tissue interface assembly is configured to receive the at least one optical signal after propagation through at least a gap between the tissue interface assembly and the tissue, and wherein the measurement system is configured to process at least the propagation pathlength to determine the state of the tissue interface assembly on the tissue as including the gap between the tissue interface assembly and the tissue.
14. The system of claim 9 , comprising:
the measurement system configured to process at least the propagation pathlength of the at least one optical signal and a detected intensity of the at least one optical signal to determine of a value of the physiological parameter when the state of the tissue interface assembly on the tissue indicates a proper application of the tissue interface assembly.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/704,517 US20150230736A1 (en) | 2012-06-12 | 2015-05-05 | Pathlength enhancement of optical measurement of physiological blood parameters |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/494,630 US9050044B2 (en) | 2012-06-12 | 2012-06-12 | Pathlength enhancement of optical measurement of physiological blood parameters |
US14/704,517 US20150230736A1 (en) | 2012-06-12 | 2015-05-05 | Pathlength enhancement of optical measurement of physiological blood parameters |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/494,630 Continuation US9050044B2 (en) | 2012-06-12 | 2012-06-12 | Pathlength enhancement of optical measurement of physiological blood parameters |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150230736A1 true US20150230736A1 (en) | 2015-08-20 |
Family
ID=49715855
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/494,630 Active 2033-02-13 US9050044B2 (en) | 2012-06-12 | 2012-06-12 | Pathlength enhancement of optical measurement of physiological blood parameters |
US14/704,517 Abandoned US20150230736A1 (en) | 2012-06-12 | 2015-05-05 | Pathlength enhancement of optical measurement of physiological blood parameters |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/494,630 Active 2033-02-13 US9050044B2 (en) | 2012-06-12 | 2012-06-12 | Pathlength enhancement of optical measurement of physiological blood parameters |
Country Status (1)
Country | Link |
---|---|
US (2) | US9050044B2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9050044B2 (en) * | 2012-06-12 | 2015-06-09 | Covidien Lp | Pathlength enhancement of optical measurement of physiological blood parameters |
KR102249824B1 (en) * | 2014-02-24 | 2021-05-10 | 삼성전자주식회사 | Apparatus and Method for sensing body imformation thereof |
WO2016178986A1 (en) * | 2015-05-01 | 2016-11-10 | Lifeq Global Limited | System and method for spo2 determination using reflective ppg |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6246892B1 (en) * | 1991-01-24 | 2001-06-12 | Non-Invasive Technology | Phase modulation spectroscopy |
US6285904B1 (en) * | 2000-03-27 | 2001-09-04 | Sandia Corporation | Method and apparatus for determining fat content of tissue |
US6356774B1 (en) * | 1998-09-29 | 2002-03-12 | Mallinckrodt, Inc. | Oximeter sensor with encoded temperature characteristic |
US6594513B1 (en) * | 2000-01-12 | 2003-07-15 | Paul D. Jobsis | Method and apparatus for determining oxygen saturation of blood in body organs |
US20030139656A1 (en) * | 1999-06-18 | 2003-07-24 | Kiani Massi E. | Pulse oximeter probe-off detection system |
US20040208390A1 (en) * | 2003-04-18 | 2004-10-21 | Medispectra, Inc. | Methods and apparatus for processing image data for use in tissue characterization |
US20060015021A1 (en) * | 2004-06-29 | 2006-01-19 | Xuefeng Cheng | Optical apparatus and method of use for non-invasive tomographic scan of biological tissues |
US20070088207A1 (en) * | 2000-08-31 | 2007-04-19 | Nellcor Puritan Bennett Inc. | Method and circuit for storing and providing historical physiological data |
US20100076319A1 (en) * | 2008-09-25 | 2010-03-25 | Nellcor Puritan Bennett Llc | Pathlength-Corrected Medical Spectroscopy |
US20120190989A1 (en) * | 2009-08-17 | 2012-07-26 | The Regents Of The University Of California | Distributed external and internal wireless sensor systems for characterization of surface and subsurface biomedical structure and condition |
US20130184745A1 (en) * | 2012-01-17 | 2013-07-18 | Infarct Reduction Technologies Inc. | Dual mode remote ischemic preconditioning devices and methods |
US9050044B2 (en) * | 2012-06-12 | 2015-06-09 | Covidien Lp | Pathlength enhancement of optical measurement of physiological blood parameters |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5119815A (en) | 1988-12-21 | 1992-06-09 | Nim, Incorporated | Apparatus for determining the concentration of a tissue pigment of known absorbance, in vivo, using the decay characteristics of scintered electromagnetic radiation |
US5413100A (en) | 1991-07-17 | 1995-05-09 | Effets Biologiques Exercice | Non-invasive method for the in vivo determination of the oxygen saturation rate of arterial blood, and device for carrying out the method |
RU2038037C1 (en) | 1992-07-20 | 1995-06-27 | Акционерное общество закрытого типа Научно-производственное предприятие "Техномедика" | Apparatus for measuring content of bilirubin in patient's subcutaneous tissues and blood |
RU2040912C1 (en) | 1993-01-05 | 1995-08-09 | Научно-инженерный центр биомедицинской радиоэлектроники института радиотехники и электроники РАН | Optical method and device for determining blood oxygenation |
US6058324A (en) | 1993-06-17 | 2000-05-02 | Non-Invasive Technology, Inc. | Examination and imaging of biological tissue |
US5555855A (en) | 1994-01-11 | 1996-09-17 | Sanshin Kogyo Kabushiki Kaisha | Water circulation system for marine engine |
WO2006124696A1 (en) | 2005-05-13 | 2006-11-23 | Children's Hospital Medical Center | Multi-wavelength spatial domain near infrared oximeter to detect cerebral hypoxia-ischemia |
US8788001B2 (en) | 2009-09-21 | 2014-07-22 | Covidien Lp | Time-division multiplexing in a multi-wavelength photon density wave system |
-
2012
- 2012-06-12 US US13/494,630 patent/US9050044B2/en active Active
-
2015
- 2015-05-05 US US14/704,517 patent/US20150230736A1/en not_active Abandoned
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6246892B1 (en) * | 1991-01-24 | 2001-06-12 | Non-Invasive Technology | Phase modulation spectroscopy |
US6356774B1 (en) * | 1998-09-29 | 2002-03-12 | Mallinckrodt, Inc. | Oximeter sensor with encoded temperature characteristic |
US20030139656A1 (en) * | 1999-06-18 | 2003-07-24 | Kiani Massi E. | Pulse oximeter probe-off detection system |
US6594513B1 (en) * | 2000-01-12 | 2003-07-15 | Paul D. Jobsis | Method and apparatus for determining oxygen saturation of blood in body organs |
US6285904B1 (en) * | 2000-03-27 | 2001-09-04 | Sandia Corporation | Method and apparatus for determining fat content of tissue |
US20070088207A1 (en) * | 2000-08-31 | 2007-04-19 | Nellcor Puritan Bennett Inc. | Method and circuit for storing and providing historical physiological data |
US20040208390A1 (en) * | 2003-04-18 | 2004-10-21 | Medispectra, Inc. | Methods and apparatus for processing image data for use in tissue characterization |
US20060015021A1 (en) * | 2004-06-29 | 2006-01-19 | Xuefeng Cheng | Optical apparatus and method of use for non-invasive tomographic scan of biological tissues |
US20100076319A1 (en) * | 2008-09-25 | 2010-03-25 | Nellcor Puritan Bennett Llc | Pathlength-Corrected Medical Spectroscopy |
US20120190989A1 (en) * | 2009-08-17 | 2012-07-26 | The Regents Of The University Of California | Distributed external and internal wireless sensor systems for characterization of surface and subsurface biomedical structure and condition |
US20130184745A1 (en) * | 2012-01-17 | 2013-07-18 | Infarct Reduction Technologies Inc. | Dual mode remote ischemic preconditioning devices and methods |
US9050044B2 (en) * | 2012-06-12 | 2015-06-09 | Covidien Lp | Pathlength enhancement of optical measurement of physiological blood parameters |
Also Published As
Publication number | Publication date |
---|---|
US9050044B2 (en) | 2015-06-09 |
US20130331710A1 (en) | 2013-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8781548B2 (en) | Medical sensor with flexible components and technique for using the same | |
US20130158413A1 (en) | Optical measurement of physiological blood parameters | |
CN108471950B (en) | System, device and method for monitoring blood oxygen saturation of transcarotomy fetus | |
AU708051B2 (en) | Sensor, method and device for optical blood oximetry | |
Mannheimer | The light–tissue interaction of pulse oximetry | |
US20120310062A1 (en) | Photon density wave based determination of physiological blood parameters | |
US8818476B2 (en) | Reflectance and/or transmissive pulse oximeter | |
US20180333053A1 (en) | Wearable device and system for acquiring physiological information of a subject | |
US20060129039A1 (en) | Apparatus for improved pulse oximetry measurement | |
JP2008532680A5 (en) | ||
US20120184831A1 (en) | Systems, devices and methods for monitoring hemodynamics | |
US20100081902A1 (en) | Medical Sensor and Technique for Using the Same | |
JP2001149349A (en) | Sensor for living body | |
US8463348B2 (en) | System and method for non-invasive monitoring of cerebral tissue hemodynamics | |
US8433382B2 (en) | Transmission mode photon density wave system and method | |
US20130253332A1 (en) | Tissue interface systems for application of optical signals into tissue of a patient | |
US8788005B1 (en) | System and method for non-invasive monitoring of cerebral tissue hemodynamics | |
US20150230736A1 (en) | Pathlength enhancement of optical measurement of physiological blood parameters | |
US9326684B2 (en) | Magnetic enhancement in determination of physiological blood parameters | |
US20130317325A1 (en) | Apparatus and method for measurement of physiological parameters in tissue of a patient | |
US20130274611A1 (en) | Optical interface systems for application of optical signals into tissue of a patient | |
JP2003202287A (en) | Scattering absorption member measuring method and device | |
US8712492B2 (en) | Photon density wave based determination of physiological blood parameters | |
Chung et al. | Signal-enhancement reflective pulse oximeter with Fresnel lens | |
US20130158412A1 (en) | Tissue interface systems for optical measurement of physiological blood parameters |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: COVIDIEN LP, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LI, YOUZHI;BAKER, CLARK R., JR.;SIGNING DATES FROM 20120608 TO 20121204;REEL/FRAME:035568/0420 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |